Abstract
Next-generation sequencing (NGS) is a trending new platform which allows cheap, quantitative, high-throughput, parallel sequencing for minority variants with frequencies less than 20% of the HIV-1 quasi-species. In clinical setting, these advantages are crucial for choosing antiretroviral drugs with low genetic barriers and will potentially benefit treatment outcomes. In this investigation, we implemented the Boxin HIV-1 NGS platform for genotyping the drug-resistance-associated variants in PR/RT regions. Plasmids with known mutations were used to analyze the accuracy, reproducibility, and reliability of the Boxin NGS assay. Variant frequencies reported by Boxin NGS and the theoretical value were highly concordant. The Bland-Altman plot and the coefficient of variation (7%) suggested that the method has excellent reproducibility and reliability. Sanger sequencing confirmed the existence of these known variants with frequencies equal or above 20%. 78 blood samples were obtained from AIDS patients and underwent PR/RT region genotyping by Sanger sequencing and Boxin NGS. 33 additional drug resistance mutations were identified by Boxin NGS, 23/33 mutations were minority variants with frequencies below 20%. 15 blood samples obtained from AIDS patients underwent PR/RT region genotyping by Sanger sequencing, Boxin NGS, and Vela NGS. The Bland-Altman plot suggested that the variant frequencies detected by Boxin and Vela were highly concordant. Moreover, Boxin NGS assay detected five more minority variants with frequencies ranged from 1% to 20%. In a series of samples collected from 2016 to 2017, Boxin NGS reported a M184V mutation with a frequency of 4.92%, 3 months earlier than this mutation was firstly detected by Vela NGS and Sanger sequencing. In conclusion, Boxin NGS had good accuracy, reproducibility, and reliability. Boxin NGS was highly concordant with Sanger sequencing and Vela NGS. In terms of genotyping HIV-1 variants in PR/RT regions, Boxin NGS was more cost-efficient and appeared to have increased sensitivity without compromising sequence accuracy.
Introduction
HIV-1 exists within a patient not as a single uniform virus, but as a "quasi-species"—a diverse population of closely related variants. When a patient undergoes antiretroviral therapy (ART), some of these variants may carry mutations that grant drug resistance.
The long-standing "gold standard" for detecting these mutations is Sanger sequencing. However, Sanger has a major blind spot: it generally cannot detect "minority variants" that make up less than 20% of the total viral population. These low-abundance drug-resistance mutations (LADRMs) are clinically critical because they can quickly become the dominant population under the selective pressure of drugs, leading to virological failure and poor patient outcomes. This paper evaluates the Boxin HIV-1 NGS platform, a new tool designed to bridge this gap by providing high-throughput, quantitative detection of these elusive minority variants.
Methods
The study implemented and evaluated the Boxin HIV-1 NGS platform (developed by Liangxin Biotechnology). The workflow utilized Ion Torrent-based deep sequencing (using Ion Plus Fragment Library and Ion Chef instruments) and a custom bioinformatics pipeline optimized for Chinese HIV-1 patient populations. This pipeline is capable of identifying 256 different mutations across the Protease (PR), Reverse Transcriptase (RT), and Integrase (IN) regions.
To establish a baseline for accuracy and reproducibility, the authors first used synthetic plasmids with known mutations at specific frequencies (5% to 50%). They then compared the Boxin platform's performance against traditional Sanger sequencing and the FDA-approved Vela Diagnostics Sentosa SQ HIV assay using real-world patient blood samples from several cohorts, including a longitudinal case study tracking a single patient over two years.
Performance and Validation
The Boxin platform demonstrated high technical precision across multiple metrics:
- Accuracy: Experimental results showed a near-perfect correlation with theoretical values ($R^2 = 0.9932$, slope = 0.8948) using plasmid standards.
- Reproducibility: The average coefficient of variation (CV) was 7%, indicating high reliability across different laboratory technicians and sequencing runs.
- Sensitivity: The platform demonstrated a lower limit of detection of 1%, significantly outperforming the 20% threshold of Sanger sequencing.
Clinical Comparison and Insights
In a cohort of 78 blood samples, Boxin identified 33 additional mutations that Sanger sequencing missed. Of these, 23 were minority variants (below 20% frequency), proving that NGS catches the "hidden" resistance that often precedes treatment failure. In a more focused 15-sample comparison, Boxin detected 18 out of 20 total identified mutations, whereas the Vela platform detected 13 and Sanger detected only 5.
One of the most compelling findings came from a longitudinal case study. The Boxin platform detected the critical M184V mutation—which causes resistance to common drugs like Lamivudine—at a frequency of 4.92% a full three months before it was detectable by either Sanger or the Vela NGS platform. This "early warning" capability could allow clinicians to adjust failing treatment regimens much sooner than currently possible.
Economic Impact and Future Directions
Beyond its technical advantages, the Boxin NGS platform offers a significant cost benefit. While Sanger sequencing costs between £430 and £1050 and the Vela NGS assay costs roughly $400 per sample, the Boxin NGS platform costs only **$40 per sample**. This 90% reduction in cost compared to leading NGS competitors makes high-sensitivity resistance testing far more accessible for routine clinical use.
While the platform shows technical excellence, a remaining clinical hurdle is defining the "threshold of significance." While variants can now be detected at 1% or 5%, more large-scale cohort studies are needed to determine exactly which low-frequency mutations necessitate an immediate change in a patient's drug regimen. Future work will also expand this validation to include the latest generation of integrase inhibitors, which are increasingly used as first-line treatments globally.
Summary updated